Finanzen von Vera Therapeutics, Inc (VERA)VERAVera Therapeutics, Inc

Evaluating the bottom line, Vera Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -91.75%, provide a clear picture of how effectively VERA converts its operational activities into shareholder value.

In the context of the broader market, VERA competes directly with industry leaders such as BCRX and ADRX. With a market capitalization of $2.01B, it holds a significant position in the sector. When comparing efficiency, VERA's gross margin of N/A stands against BCRX's 98.24% and ADRX's N/A. Such benchmarking helps identify whether Vera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported substantial net losses, with Q2 2026 net income at -109,473,000 USD and a negative EPS of -1.52, highlighting ongoing financial struggles.